- Neuroendocrine Cancer
- Newly Diagnosed
- Carcinoid & Neuroendocrine Tumor Patient Community
- Doctor Database
- Clinical Trials
- Educational Resources
- Additional Resources
- Join Us For a Cure
- Researching Funding Opportunities
- Current Research Grants
- Previous Research Grants
- Research Approach
- Board of Scientific Advisors
- About Us
- CFCF News
- Founder Nancy Lindholm
- Corporate Sponsorship
Lauren and Nick.
Dave, Suzi, Lauren - Philadelphia, PA
1st World Congress on Ga-68 and Peptide Receptor Radionuclide Therapy (PRRNT)
The Caring for Carcinoid Foundation has always been committed to supporting patients by providing them with complete and up to date information regarding all potential treatment options. On our website and YouTube channel, Caring4Carcinoid, we provide information for patients seeking to learn more about peptide receptor radiotherapy (PRRT).
Most recently Dr. Richard Baum announced the 1st World Congress on Ga-68 and Peptide Receptor Radionuclide Therapy.
In this upcoming meeting, Dr. Baum and his co-organizer Dr. Frank Rosch aim to educate medical professionals not just about PRRT (also called PRRNT), but also about personalized treatment with PRRT. The program includes sessions on imaging and how specialized imaging tests can be used to precisely tailor treatment on a patient-by-patient basis; in effect, delivering personalized medicine to patients.
Previously CFCF worked with both Dr. Baum and Bill Claxton from Carcinoid Neuroendocrine Tumor Society (CNETS) Singapore to make videos from a Seminar in Singapore available to patients. The videos are:
CFCF also conducted its own Expert Interview with Dr. Baum and CFCF Director of Patient Support, Ben Blackwood. In the interview Dr. Baum describes his experience in treating patients at the Neuroendocrine Tumor Clinic at Bad Berka where over 1,000 patients are treated annually. Please click here to listen to this interview.
In both the videos and the interview, Dr. Baum reinforces several important themes for patients with neuroendocrine tumors based on his experience in treating neuroendocrine tumor patients:
1. It is important for neuroendocrine tumor patients to seek treatment in a multidisciplinary center.
2. It is important for neuroendocrine tumor patients to seek treatment from physicians with experience and expertise in treating neuroendocrine tumor patients.
3. Because neuroendocrine tumors are heterogeneous (meaning no two are alike), it is important for all treatment to be personalized to the individual patient.
In the interviews Dr. Baum describes PRRT as a targeted therapy that, for certain patients, can destroy tumor cells while leaving other body cells unharmed. Dr. Baum selects patients for treatment with PRRT based on diagnostic imaging and other diagnostic tests.
Any patient considering PRRT or any therapy should consult with a physician well-versed in treating patients with neuroendocrine tumors. For help in finding such a physician please check out Doctor Database or contact us.